Background The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.
Primary objective The primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease, or residual disease up to 2.5 mm in maximum dimension.
Study hypothesis We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with primary FIGO stage III epithelial ovarian cancer.
Trial design This international, randomized, open-label, phase III trial will enroll 538 patients with newly diagnosed FIGO stage III epithelial ovarian cancer. Following complete or near-complete (residual disease ≤2.5 mm) primary cytoreduction, patients are randomly allocated (1:1) to receive HIPEC or no HIPEC. All patients will receive six courses of platinum-paclitaxel chemotherapy, and maintenance PARP-inhibitor or bevacizumab according to current guidelines.
Major eligibility criteria Patients with FIGO stage III primary epithelial ovarian, fallopian tube, or primary peritoneal cancer are eligible after complete or near-complete primary cytoreductive surgery. Patients with resectable umbilical, spleen, or local bowel lesions may be included. Enlarged extra-abdominal lymph nodes should be negative on FDG-PET or fine-needle aspiration/biopsy.
Primary endpoint The primary endpoint is overall survival.
Sample size To detect a HR of 0.67 in favor of HIPEC, 200 overall survival events are required. With an expected accrual period of 60 months and 12 months additional follow-up, 538 patients need to be randomized.
Estimated dates for completing accrual and presenting results The OVHIPEC-2 trial started in January 2020 and primary analyses are anticipated in 2026.
Trial registration ClinicalTrials.gov:NCT03772028
- ovarian cancer
- surgical oncology
- peritoneal neoplasms
- surgical procedures, operative
Statistics from Altmetric.com
Collaborators The International OVHIPEC-2 Steering Committee (in alphabetical order): N Bakrin, S Banerjee, S Barry, DP Barton, D Brennan, PE Colombo, M Deraco, WJ van Driel, A Fagotti, R Farrell, R Grisham, BJ Mosgaard, I McNeish, L Perrin, GS Sonke, O Zivanovic. The Dutch OVHIPEC group (in alphabetical order): HJG Arts, I Boere, GJ Creemers, WJ van Driel, KN Gaarenstroom, M van Gent, M van Ham, B Hellebrekers, R Hermans, I de Hingh, SN Koole, JR Kroep, CD de Kroon, R Lalisang, S Lambrechts, P Ottevanger, N Reesink, V Retel, AKL Reyners, EM Roes, HWR Schreuder, GS Sonke, RM van Stein, A Thijs, A Westermann, PO Witteveen, A Wymenga, R Yigit. Dutch Gynaecological Oncology Group (DGOG), Dutch Peritoneal Oncology Group (DPOG).
Contributors Conception and study design: WJvD, GS, SK, RvS, OVHIPEC-2 Steering Committee, Dutch OVHIPEC group. Statistical calculations: KS. Manuscript writing: SK, WJvD, GS. Manuscript editing and reviewing: RvS, KS, DB, LP, DB, OZ, BJM, AF, PE-C, GS, WJvD. Final approval of manuscript: SK, WJvD, GS.
Funding The trial is funded by the Dutch Cancer Society (DCS), the Netherlands Organization for Health Research and Development (ZonMW), and the Coverage with Evidence Development (CED) program of the Dutch Ministry of Health.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data will be available upon request
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.